toggle visibility Search & Display Options

Select All    Deselect All
 |   | 
  Record Links
Author (up) Keating, G.M. url  openurl
  Title Posaconazole Type Journal Article
  Year 2005 Publication Drugs Abbreviated Journal Drugs  
  Volume 65 Issue 11 Pages 1553-67; discussion 1568-9  
  Keywords Animals; Antifungal Agents/administration & dosage/adverse effects/pharmacokinetics/pharmacology/*therapeutic use; Clinical Trials as Topic; Fungi/drug effects; Humans; Mycoses/*drug therapy/microbiology; Triazoles/administration & dosage/adverse effects/pharmacokinetics/pharmacology/*therapeutic use  
  Abstract Posaconazole is a triazole antifungal agent, administered as an oral suspension, with an extended spectrum of in vitro activity. Posaconazole 800 mg/day demonstrated clinically relevant activity against a range of fungi in patients with invasive fungal infections who were refractory to, or intolerant of, other antifungal therapy in an open-label, multicentre, phase III study (330 patients received posaconazole and 279 patients served as external controls). In aspergillosis, the global response success rate at the end-of-therapy visit (primary endpoint) was significantly higher in posaconazole recipients than in external controls (42% vs 26%). Posaconazole was also associated with overall success rates of 54% in zygomycosis, 46% in fusariosis, 43% in Pseudallescheria infection, 80% in phaeohyphomycosis and 100% in histoplasmosis. Success rates were 48% in refractory candidiasis, 69% in refractory coccidioidomycosis, 48% in refractory cryptococcal infection and 82% in refractory chromoblastomycosis or mycetoma. Posaconazole also demonstrated potential in febrile neutropenia in an open-label phase II study (success rate of 81% 7 days after the end of treatment). In a noncomparative, multicentre, phase III study in patients with advanced HIV infection who had azole-refractory oropharyngeal and/or oesophageal candidiasis, posaconazole 400 or 800 mg/day resulted in a clinical response in 132 of 176 patients (75%). Oral posaconazole suspension was generally well tolerated in patients with invasive fungal infections, including patients who received treatment for >or=1 year.  
  Address Adis International Limited, Auckland, New Zealand.  
  Corporate Author Thesis  
  Publisher Place of Publication Editor  
  Language English Summary Language Original Title  
  Series Editor Series Title Abbreviated Series Title  
  Series Volume Series Issue Edition  
  ISSN 0012-6667 ISBN Medium  
  Area Expedition Conference  
  Notes PMID:16033292 Approved no  
  Call Number refbase @ user @ Serial 23365  
Permanent link to this record
Select All    Deselect All
 |   | 

Save Citations:
Export Records: